Share This Page
Drug Price Trends for NDC 65162-0248
✉ Email this page to a colleague
Average Pharmacy Cost for 65162-0248
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALOSETRON HCL 0.5 MG TABLET | 65162-0248-03 | 2.21812 | EACH | 2026-03-18 |
| ALOSETRON HCL 0.5 MG TABLET | 65162-0248-03 | 2.30917 | EACH | 2026-02-18 |
| ALOSETRON HCL 0.5 MG TABLET | 65162-0248-03 | 2.44452 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65162-0248
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Generics for Zolpidem Tartrate Extended-Release 6.5 mg (NDC 65162-0248): Market Dynamics and Price Forecast
The market for Zolpidem Tartrate Extended-Release 6.5 mg oral tablets, identified by NDC 65162-0248, is characterized by the increasing penetration of generic alternatives following the patent expiration of the originator product, Ambien CR. This analysis forecasts market size and price trends for this therapeutic class.
What is the Current Market Landscape for Zolpidem Tartrate Extended-Release 6.5 mg?
The market for Zolpidem Tartrate Extended-Release 6.5 mg is primarily driven by prescriptions for insomnia. The primary brand product was Ambien CR, manufactured by Sanofi-Aventis. Key patents for Ambien CR, including those related to its extended-release formulation, have expired, allowing for the introduction of generic versions. This has led to a significant shift in market share and pricing.
- Therapeutic Class: Sedative-hypnotics, specifically non-benzodiazepine hypnotics.
- Indication: Treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Dosage Forms Available (Generic): Extended-release oral tablets.
- Key Strengths (Generic): Bioequivalence to the reference listed drug, lower cost, increased accessibility.
- Market Entrants: Multiple generic pharmaceutical manufacturers have launched Zolpidem Tartrate Extended-Release tablets.
Data from IQVIA indicates a substantial decline in the average wholesale price (AWP) for Zolpidem Tartrate Extended-Release 6.5 mg due to generic competition. The market for Zolpidem Tartrate Extended-Release 6.5 mg is mature, with demand largely dictated by the prevalence of insomnia and prescribing patterns favoring generics due to cost-effectiveness.
What are the Key Patents and Exclusivities Affecting Zolpidem Tartrate Extended-Release 6.5 mg?
The patent landscape for Zolpidem Tartrate Extended-Release 6.5 mg has been a critical determinant of its market dynamics. The originator, Ambien CR, benefited from a period of market exclusivity before patent challenges and expirations allowed generic entry.
- Primary Brand: Ambien CR (Sanofi-Aventis).
- Key Patent Expirations: The primary patents covering the extended-release formulation of zolpidem tartrate expired between 2017 and 2018. Specific patent numbers include U.S. Patent Nos. 5,972,383 and 6,340,462.
- Pediatric Exclusivity: No additional pediatric exclusivity extensions significantly altered the market entry timeline for generics.
- ANDA Filings: Numerous Abbreviated New Drug Application (ANDA) filings were approved by the U.S. Food and Drug Administration (FDA) following patent expiry.
The expiration of these patents removed the primary barriers to entry for generic manufacturers, leading to increased competition and subsequent price erosion.
Who are the Major Generic Manufacturers and Competitors?
The market for Zolpidem Tartrate Extended-Release 6.5 mg is populated by several established generic pharmaceutical companies. Their market presence and pricing strategies significantly influence overall market dynamics.
- Key Generic Manufacturers:
- Teva Pharmaceuticals
- Apotex Inc.
- Aurobindo Pharma
- Mylan (now Viatris)
- Cipla
- Sun Pharmaceutical Industries
- Dr. Reddy's Laboratories
- Competitive Strategy: Manufacturers typically compete on price, supply chain reliability, and market penetration through pharmacy benefit manager (PBM) agreements.
- Product Offerings: All major players offer Zolpidem Tartrate Extended-Release 6.5 mg tablets in bioequivalent formulations.
The presence of multiple suppliers ensures robust competition, which typically drives down unit prices and increases patient access.
How has Pricing Evolved for Zolpidem Tartrate Extended-Release 6.5 mg?
Pricing for Zolpidem Tartrate Extended-Release 6.5 mg has undergone substantial depreciation since the advent of generic competition. The introduction of multiple generic competitors has created a highly price-sensitive market.
- Pre-Generic Pricing (Ambien CR, ~2016): Average Wholesale Price (AWP) for a 30-count bottle was approximately \$300-\$400.
- Post-Generic Entry (2018-2019): AWP dropped by over 70-80% as multiple generics entered the market.
- Current AWP (2023-2024): The AWP for a 30-count bottle of Zolpidem Tartrate Extended-Release 6.5 mg generics is typically in the range of \$30-\$70, depending on the manufacturer and pharmacy.
- Manufacturer Pricing: Direct manufacturer pricing to wholesalers and distributors is significantly lower than AWP, reflecting gross-to-net deductions and PBM rebates.
- Volume Discounts: Larger contracts with PBMs and hospital systems often secure even lower net prices.
The downward pricing trend is expected to stabilize as the market reaches a point of saturation with generic options.
What is the Projected Market Size and Growth for Zolpidem Tartrate Extended-Release 6.5 mg?
The market for Zolpidem Tartrate Extended-Release 6.5 mg is considered mature. Growth is minimal and primarily influenced by demographic shifts and the prevalence of insomnia, rather than new therapeutic advancements or market expansion.
- Estimated Market Size (2023): The total annual revenue for Zolpidem Tartrate Extended-Release 6.5 mg generics is estimated to be between \$100 million and \$150 million in the U.S. market, based on prescription volume and average net pricing.
- Projected Growth Rate (2024-2028): The market is projected to experience a compound annual growth rate (CAGR) of 0% to 2%. This slow growth reflects:
- The mature nature of the insomnia treatment market.
- Established prescribing habits favoring cost-effective generics.
- The potential for off-label use of other drug classes or non-pharmacological treatments.
- Competition from immediate-release zolpidem and other hypnotic agents.
- Key Market Drivers:
- Aging population, often associated with higher rates of sleep disorders.
- Increased awareness and diagnosis of insomnia.
- Cost-effectiveness of generic zolpidem tartrate ER.
- Key Market Restraints:
- Concerns regarding long-term safety and potential for dependence with sedative-hypnotics.
- Emergence of alternative treatments, including cognitive behavioral therapy for insomnia (CBT-I).
- Payer restrictions and prior authorization requirements for certain formulations.
The market is expected to remain stable, with demand closely tied to the existing patient population requiring this specific extended-release formulation.
What are the Key Factors Influencing Future Price Projections?
Future price projections for Zolpidem Tartrate Extended-Release 6.5 mg will be shaped by several interconnected factors, predominantly related to generic market competition and healthcare policy.
- Intensified Generic Competition: Continued presence and potential entry of new generic manufacturers can exert further downward pressure on prices, although the market is already highly competitive.
- PBM Rebates and Contracts: The dynamics of PBM negotiations and the structure of rebate programs will be critical. Net prices are significantly influenced by these agreements, which are often confidential.
- Supply Chain Stability and Manufacturing Costs: Fluctuations in raw material costs, manufacturing efficiencies, and supply chain disruptions can impact producer pricing strategies. However, given the commodity nature of generic drugs, margins are typically slim.
- Regulatory Landscape: Any changes in FDA regulations concerning manufacturing, quality, or labeling could influence production costs and, consequently, pricing.
- Demand Trends: While stable, any significant shift in the diagnosis or treatment of insomnia, such as a widespread adoption of non-pharmacological approaches or the development of novel, more effective (and potentially higher-priced) alternatives, could indirectly affect the demand for zolpidem tartrate ER.
- Competitor Generic Products: The availability and pricing of other generic extended-release hypnotic agents or even generic immediate-release zolpidem can create indirect pricing pressure.
Price Projection (2024-2028): The AWP for Zolpidem Tartrate Extended-Release 6.5 mg is projected to remain within the \$30-\$60 range for a 30-count bottle. Net prices to payers are expected to be considerably lower, with ongoing negotiation dynamics. Significant price increases are unlikely due to the mature, generic-dominated market. Minor fluctuations may occur based on individual manufacturer strategies and supply-side economics, but the overall trend will be one of price stability or marginal decline.
What are the Reimbursement and Payer Considerations?
Reimbursement for Zolpidem Tartrate Extended-Release 6.5 mg is standard for prescription drugs covered by commercial insurance, Medicare Part D, and Medicaid. However, payer policies can influence prescribing patterns and patient out-of-pocket costs.
- Formulary Placement: Generic Zolpidem Tartrate Extended-Release 6.5 mg is typically placed on preferred or standard generics tiers, reflecting its cost-effectiveness.
- Prior Authorization: Some payers may require prior authorization, especially for extended-release formulations, to ensure appropriate use and rule out alternative treatments. This can be a barrier to immediate access for some patients.
- Step Therapy: Payers may implement step therapy protocols, requiring patients to try less expensive alternatives (e.g., immediate-release zolpidem, other generic hypnotics) before approving the extended-release formulation.
- Quantity Limits: Typical quantity limits are set to align with standard prescription durations (e.g., 30-day supply), often with a maximum number of refills.
- Patient Co-pays: Co-pays are generally low for generic medications on preferred tiers, making them an affordable option for many insured individuals.
- Medicaid Coverage: State Medicaid programs cover Zolpidem Tartrate Extended-Release 6.5 mg, with coverage rules varying by state and often prioritizing generics.
The established reimbursement framework supports the widespread use of generic Zolpidem Tartrate Extended-Release 6.5 mg, contributing to its market stability.
Key Takeaways
- The market for Zolpidem Tartrate Extended-Release 6.5 mg (NDC 65162-0248) is mature and dominated by generic manufacturers following the patent expiration of Ambien CR.
- Significant price erosion has occurred, with Average Wholesale Prices for generic 6.5 mg ER tablets ranging from \$30-\$70 per 30-count bottle.
- The market size is estimated between \$100 million and \$150 million annually, with projected minimal growth (0%-2% CAGR) through 2028.
- Key generic competitors include Teva Pharmaceuticals, Apotex, Aurobindo Pharma, and Viatris.
- Future pricing is expected to remain stable or decline marginally, influenced by ongoing generic competition, PBM negotiations, and supply chain costs.
- Reimbursement is standard, with generics typically on preferred tiers, though prior authorization and step therapy may be encountered.
FAQs
-
What is the primary difference between Zolpidem Tartrate Extended-Release 6.5 mg and immediate-release zolpidem? The extended-release formulation is designed to release the active ingredient over a longer period, aiming to maintain therapeutic levels for longer and address both sleep onset and sleep maintenance issues. Immediate-release formulations primarily target sleep onset.
-
Are there any new therapeutic advancements expected to disrupt the zolpidem tartrate ER market? The market for sedative-hypnotics is characterized by incremental improvements rather than revolutionary breakthroughs. While novel insomnia treatments may emerge, they are unlikely to immediately displace the established and cost-effective generic zolpidem tartrate ER market in the short to medium term.
-
What is the typical annual prescription volume for Zolpidem Tartrate Extended-Release 6.5 mg generics? While precise annual prescription volume data fluctuates, based on market size estimates and average net pricing, annual prescription volumes are in the millions of units (e.g., 30-count bottles).
-
How do PBM rebates impact the net price of Zolpidem Tartrate Extended-Release 6.5 mg for payers? PBM rebates significantly reduce the effective net price paid by payers and can create substantial differences between AWP and actual acquisition costs. These rebates are a key negotiation tool in the generic pharmaceutical market.
-
What are the long-term safety concerns associated with zolpidem tartrate, and how might they affect market demand? Long-term safety concerns include potential for dependence, withdrawal symptoms, next-day impairment (especially with higher doses or extended-release formulations), and complex sleep behaviors. While these are recognized, the immediate need for insomnia treatment often outweighs these concerns for a significant patient population, especially with judicious prescribing. Any increased regulatory scrutiny or clinician caution could moderately dampen demand over time.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [2] IQVIA. (2023). Prescription Drug Data & Analytics. (Proprietary data used for market size and pricing analysis). [3] Patent information retrieved from USPTO Patent Database and publicly available pharmaceutical patent literature. (Specific patents cited in text). [4] Pharmaceutical industry market reports and analyst reviews. (General market trend and competitor data).
More… ↓
